ScienceDaily Article highlights recent paper from Dr. Adam Alani’s lab
“Researachers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment — to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination.
“The approach, called a ‘metronomic dosage regimen,’ uses significantly lower doses of chemotherapeutic drugs but at more frequent time intervals. This would have multiple goals of killing cancer cells, creating a hostile biological environment for their growth, reducing toxicity from the drug regimen and avoiding the development of resistance to the cancer drugs
being used.
“A system just published in Chemistry of Materials by a group of researchers from Oregon and the United Kingdom offers an even more effective way to deliver such drugs and may be able to greatly improve this approach, scientists say. Further testing is needed in both animals and humans for safety and efficacy.
“’This new system takes some existing cancer therapy drugs for ovarian cancer, delivers both of them at the same time and allows them to work synergistically,’ said Adam Alani, and associate professor in the Oregon State University/Oregon Health & Science University College of Pharmacy, and lead author on the new study.”
To read the full article, click here.
Original paper, Combinatorial Polymeric Conjugated Micelles with Dual Cytotoxic and Antiangiogenic Effects for the Treatment of Ovarian Cancer, published by Chemistry of Materials, 2016.